BACKGROUND: A comprehensive, reliable, and valid measurement system is needed to monitor changes in children with neurological conditions who experience lifelong functional limitations. OBJECTIVE: This article describes the development and psychometric properties of the pediatric version of the Quality of Life in Neurological Disorders (Neuro-QOL) measurement system. METHODS: The pediatric Neuro-QOL consists of generic and targeted measures. Literature review, focus groups, individual interviews, cognitive interviews of children and consensus meetings were used to identify and finalize relevant domains and item content. Testing was conducted on 1018 children aged 10 to 17 years drawn from the US general population for generic measures and 171 similarly aged children with muscular dystrophy or epilepsy for targeted measures. Dimensionality was evaluated using factor analytic methods. For unidimensional domains, item parameters were estimated using item response theory models. Measures with acceptable fit indices were calibrated as item banks; those without acceptable fit indices were treated as summary scales. RESULTS: Ten measures were developed: 8 generic or targeted banks (anxiety, depression, anger, interaction with peers, fatigue, pain, applied cognition, and stigma) and 2 generic scales (upper and lower extremity function). The banks reliably (r > 0.90) measured 63.2% to 100% of the children tested. CONCLUSIONS: The pediatric Neuro-QOL is a comprehensive measurement system with acceptable psychometric properties that could be used in computerized adaptive testing. The next step is to validate these measures in various clinical populations.
BACKGROUND: A comprehensive, reliable, and valid measurement system is needed to monitor changes in children with neurological conditions who experience lifelong functional limitations. OBJECTIVE: This article describes the development and psychometric properties of the pediatric version of the Quality of Life in Neurological Disorders (Neuro-QOL) measurement system. METHODS: The pediatric Neuro-QOL consists of generic and targeted measures. Literature review, focus groups, individual interviews, cognitive interviews of children and consensus meetings were used to identify and finalize relevant domains and item content. Testing was conducted on 1018 children aged 10 to 17 years drawn from the US general population for generic measures and 171 similarly aged children with muscular dystrophy or epilepsy for targeted measures. Dimensionality was evaluated using factor analytic methods. For unidimensional domains, item parameters were estimated using item response theory models. Measures with acceptable fit indices were calibrated as item banks; those without acceptable fit indices were treated as summary scales. RESULTS: Ten measures were developed: 8 generic or targeted banks (anxiety, depression, anger, interaction with peers, fatigue, pain, applied cognition, and stigma) and 2 generic scales (upper and lower extremity function). The banks reliably (r > 0.90) measured 63.2% to 100% of the children tested. CONCLUSIONS: The pediatric Neuro-QOL is a comprehensive measurement system with acceptable psychometric properties that could be used in computerized adaptive testing. The next step is to validate these measures in various clinical populations.
Authors: Bryce B Reeve; Ron D Hays; Jakob B Bjorner; Karon F Cook; Paul K Crane; Jeanne A Teresi; David Thissen; Dennis A Revicki; David J Weiss; Ronald K Hambleton; Honghu Liu; Richard Gershon; Steven P Reise; Jin-shei Lai; David Cella Journal: Med Care Date: 2007-05 Impact factor: 2.983
Authors: D P Shackleton; D G A Kasteleijn-Nolst Trenité; A J M de Craen; J P Vandenbroucke; R G J Westendorp Journal: Neurology Date: 2003-07-08 Impact factor: 9.910
Authors: Marij E Roebroeck; Reidun Jahnsen; Carlos Carona; Ruth M Kent; M Anne Chamberlain Journal: Dev Med Child Neurol Date: 2009-08 Impact factor: 5.449
Authors: Ashley Wilder Smith; Sandra A Mitchell; Cheryl K De Aguiar; Claudia Moy; William T Riley; Molly V Wagster; Ellen M Werner Journal: Transl Behav Med Date: 2016-09 Impact factor: 3.046
Authors: Hilary Bertisch; Frederick P Rivara; Pamela A Kisala; Jin Wang; Keith Owen Yeates; Dennis Durbin; Mark R Zonfrillo; Michael J Bell; Nancy Temkin; David S Tulsky Journal: Qual Life Res Date: 2017-03-07 Impact factor: 4.147
Authors: Jin-Shei Lai; Cindy J Nowinski; Frank Zelko; Katy Wortman; James Burns; Douglas R Nordli; David Cella Journal: Epilepsy Behav Date: 2015-04-07 Impact factor: 2.937
Authors: Molly M Fuentes; Jin Wang; Juliet Haarbauer-Krupa; Keith Owen Yeates; Dennis Durbin; Mark R Zonfrillo; Kenneth M Jaffe; Nancy Temkin; David Tulsky; Hilary Bertisch; Frederick P Rivara Journal: Pediatrics Date: 2018-04-19 Impact factor: 7.124
Authors: John M Salsman; David Victorson; Seung W Choi; Amy H Peterman; Allen W Heinemann; Cindy Nowinski; David Cella Journal: Qual Life Res Date: 2013-03-23 Impact factor: 4.147
Authors: Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan Journal: Muscle Nerve Date: 2013-05-16 Impact factor: 3.217